LakeShore Biopharma (LSB) has released an update.
LakeShore Biopharma has submitted a Biologics License Application to the Drug Regulatory Authority of Pakistan for its PIKA rabies vaccine, which promises faster immune response and could significantly reduce the rabies burden in high-prevalence countries like Pakistan. The vaccine’s accelerated one-week regimen has shown promising results in trials, potentially making rabies vaccines more accessible and effective. This advancement underscores LakeShore’s commitment to addressing global health challenges through innovative biotechnology.
For further insights into LSB stock, check out TipRanks’ Stock Analysis page.
